Trial Outcomes & Findings for Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region (NCT NCT00422227)

NCT ID: NCT00422227

Last Updated: 2010-08-30

Results Overview

ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

300 participants

Primary outcome timeframe

16 weeks

Results posted on

2010-08-30

Participant Flow

Subjects were recruited in the Asia-Pacific Region from June 2007 to October 2008.

Screening of subjects occurred up to 2 weeks before randomization followed by a treatment phase of 16 weeks and a 2-week safety follow up.

Participant milestones

Participant milestones
Measure
ETN/MTX
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Overall Study
STARTED
197
103
Overall Study
COMPLETED
193
88
Overall Study
NOT COMPLETED
4
15

Reasons for withdrawal

Reasons for withdrawal
Measure
ETN/MTX
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Overall Study
Adverse Event
3
8
Overall Study
Lost to Follow-up
1
3
Overall Study
Withdrawal by Subject
0
4

Baseline Characteristics

Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Total
n=300 Participants
Total of all reporting groups
Age Continuous
48.38 years
STANDARD_DEVIATION 11.98 • n=39 Participants
48.52 years
STANDARD_DEVIATION 11.25 • n=41 Participants
48.43 years
STANDARD_DEVIATION 11.72 • n=35 Participants
Sex: Female, Male
Female
180 Participants
n=39 Participants
91 Participants
n=41 Participants
271 Participants
n=35 Participants
Sex: Female, Male
Male
17 Participants
n=39 Participants
12 Participants
n=41 Participants
29 Participants
n=35 Participants

PRIMARY outcome

Timeframe: 16 weeks

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.

Outcome measures

Outcome measures
Measure
ETN/MTX
n=194 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=98 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks
434.83 Units on a scale
Standard Error 29.18
289.54 Units on a scale
Standard Error 36.11

SECONDARY outcome

Timeframe: Week 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

Response includes improvement in tender or swollen joints as well as 20 percent improvement in three of the other five criteria. Required: ≥ 20%, 50% or 70% improvement in tender joint count ≥ 20% , 50% or 70% improvement in swollen joint count and at least 20%, 50%, 70% improvement in 3 of the following 5:Patient pain assessment , Patient global assessment ,Physician global assessment, Patient self-assessed disability.

Outcome measures

Outcome measures
Measure
ETN/MTX
n=194 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=98 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
ACR 20
78.87 Percentage of Participants
58.16 Percentage of Participants
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
ACR 50
56.70 Percentage of Participants
34.69 Percentage of Participants
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
ACR 70
19.07 Percentage of Participants
7.14 Percentage of Participants

SECONDARY outcome

Timeframe: Week 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)
Low Disease (DAS28 <3.2)
39.09 Percentage of Participants
18.45 Percentage of Participants
Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)
Remission (DAS28 <2.6)
15.74 Percentage of Participants
7.77 Percentage of Participants

SECONDARY outcome

Timeframe: Week 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percent Change From Baseline in DAS28 at Week 16
38.32 Percent change
27.46 Percent change

SECONDARY outcome

Timeframe: Week 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

EULAR Response Criteria DAS28) improvement at week 16. Good response was defined as \>1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4. Non-responders were participants with improvement of ≤0.6 or participants with improvement of \>0.6 but ≤1.2 and DAS attained during follow-up of \>3.7. Remaining participants were classified as moderate. Scores of good and moderate were considered to have therapeutic response.

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response
87.82 Percentage of Participants
73.79 Percentage of Participants

SECONDARY outcome

Timeframe: Week 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2
≥0.6
91.37 Percentage of Participants
78.64 Percentage of Participants
Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2
≥1.2
82.74 Percentage of Participants
66.02 Percentage of Participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

Participant's assessment of pain - A horizontal pain visual analog scale (VAS) (0-100 mm) is used to assess the participants current level of pain; 0 = no pain and 100 = worst pain. Swollen joint count - ACR swollen joint count, an assessment of 28 joints. Joints are classified as either swollen or not swollen.

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 2
34.17 Percent change
27.68 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 4
46.11 Percent change
36.71 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 8
55.48 Percent change
49.71 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 12
65.65 Percent change
55.55 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Painful Joints - Week 16
68.99 Percent change
57.31 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 2
38.59 Percent change
21.32 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 4
49.33 Percent change
27.72 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 8
59.91 Percent change
44.19 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 12
67.97 Percent change
50.48 Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Swollen Joints - Week 16
73.83 Percent change
56.32 Percent change

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

The Physician Global Assessment of Disease Activity: The participant's disease activity is estimated over the last two - three days by the physician; A zero (0) means no disease activity and a ten (10) means extreme disease activity. The Subject Global Assessment of Disease Activity: The participant assesses overall arthritis activity. A zero (0) means no disease activity and a ten (10) means extreme disease activity.

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 2
30.40 Percent change
11.83 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 4
39.58 Percent change
22.81 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 8
45.86 Percent change
35.41 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 12
55.00 Percent change
38.67 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Physician Global Assessment - Week 16
62.05 Percent change
45.04 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 2
21.84 Percent change
7.24 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 4
28.94 Percent change
19.22 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 8
34.92 Percent change
26.08 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 12
43.18 Percent change
30.10 Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Subject Global Assessment - Week 16
50.76 Percent change
30.55 Percent change

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

The duration of morning stiffness on the day of examination should be determined by asking the following two questions: When did you awaken this morning? When were you able to resume your normal activities without stiffness? Duration of morning stiffness is equal to the time elapsed between the above two times in minutes; If none is present enter 0, If morning stiffness is still continuing, please indicate average of duration of stiffness over the past 3 days. If stiffness persists the entire day 1440 minutes (24h x 60 minutes) should be recorded.

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 2
54.92 Percent change
16.43 Percent change
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 4
63.85 Percent change
33.22 Percent change
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 8
73.41 Percent change
37.35 Percent change
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 12
79.76 Percent change
52.76 Percent change
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Week 16
80.55 Percent change
46.77 Percent change

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 16

Population: The mITT population, defined as all randomly assigned subjects who received at least 1 dose of ETN or MTX in the ETN group or 1 dose of usual DMARD therapy medication or MTX in the usual DMARD therapy group and had at least 1 postbaseline assessment.

VAS, participant indicates by marking a vertical line at an appropriate position through a horizontal line. The length of the line measures from left (in mm) and the value (in mm) is recorded. General Health VAS, "in general how would you rate your heath over the last 2-3 weeks", 0mm equals very well and 100mm equals extremely bad. Pain VAS: "indicate the amount of pain experienced during the last 2-3 days", 0 mm equals no pain and 100 mm equals pain as bad as it can be. Fatigue VAS: "how fatigued or tired have you been over the last week", range =No Fatigue - Extremely Fatigued.

Outcome measures

Outcome measures
Measure
ETN/MTX
n=197 Participants
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 Participants
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 2
21.14 Percent change
8.88 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 4
30.61 Percent change
22.78 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 8
38.57 Percent change
27.86 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 12
42.10 Percent change
30.26 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
General Health - Week 16
50.49 Percent change
33.89 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 2
27.59 Percent change
9.99 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 4
34.73 Percent change
22.98 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 8
42.97 Percent change
29.14 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 12
48.46 Percent change
33.97 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Pain - Week 16
54.42 Percent change
36.45 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 2
20.90 Percent change
6.63 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 4
30.87 Percent change
19.00 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 8
35.92 Percent change
21.82 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 12
39.65 Percent change
28.65 Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Fatigue - Week 16
46.92 Percent change
30.04 Percent change

Adverse Events

ETN/MTX

Serious events: 6 serious events
Other events: 66 other events
Deaths: 0 deaths

DMARD/MTX

Serious events: 3 serious events
Other events: 71 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
ETN/MTX
n=197 participants at risk
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 participants at risk
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Cardiac disorders
Myocardial infarction
0.51%
1/197
0.00%
0/103
Gastrointestinal disorders
Gastrointestinal haemorrhage
0.51%
1/197
0.00%
0/103
General disorders
Non-cardiac chest pain
0.51%
1/197
0.00%
0/103
Infections and infestations
Cellulitis
0.51%
1/197
0.00%
0/103
Infections and infestations
Herpes zoster
0.51%
1/197
0.00%
0/103
Infections and infestations
Pneumocystis jiroveci pneumonia
0.51%
1/197
0.00%
0/103
Infections and infestations
Pneumonia bacterial
0.00%
0/197
0.97%
1/103
Injury, poisoning and procedural complications
Fall
0.51%
1/197
0.00%
0/103
Injury, poisoning and procedural complications
Muscle strain
0.51%
1/197
0.00%
0/103
Injury, poisoning and procedural complications
Pelvic fracture
0.51%
1/197
0.00%
0/103
Injury, poisoning and procedural complications
Road traffic accident
0.51%
1/197
0.00%
0/103
Investigations
Alanine aminotransferase increased
0.00%
0/197
0.97%
1/103
Investigations
Aspartate aminotransferase increased
0.00%
0/197
0.97%
1/103
Investigations
Transaminases increased
0.00%
0/197
0.97%
1/103

Other adverse events

Other adverse events
Measure
ETN/MTX
n=197 participants at risk
Etanercept (ETN) was administered subcutaneous (SC) bi-weekly (BIW) (eg, on Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday). Each dose of ETN was administered as 1 SC injection.
DMARD/MTX
n=103 participants at risk
Methotrexate (MTX) was taken orally once weekly on the same day of the week (as a single dose or 2 divided doses on the same day) at the same dose subjects were taking at the time of screening. The dose and administration of usual disease-modifying antirheumatic drug (DMARD) therapy followed the approved local label or recommendations. Subjects took commercially available MTX and usual DMARD therapy.
Blood and lymphatic system disorders
Leukopenia
2.0%
4/197
7.8%
8/103
Gastrointestinal disorders
Nausea
2.0%
4/197
7.8%
8/103
General disorders
Pyrexia
3.0%
6/197
5.8%
6/103
Infections and infestations
Upper respiratory tract infection
13.7%
27/197
15.5%
16/103
Investigations
Alanine aminotransferase increased
5.6%
11/197
14.6%
15/103
Investigations
Aspartate aminotransferase increased
3.6%
7/197
10.7%
11/103
Respiratory, thoracic and mediastinal disorders
Cough
3.6%
7/197
6.8%
7/103

Additional Information

U. S. Contact Center

Wyeth

Results disclosure agreements

  • Principal investigator is a sponsor employee The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.
  • Publication restrictions are in place

Restriction type: OTHER